2Q EARNINGS: Amgen cutting up to 2,900 jobs to reinvest in pipeline
This article was originally published in Scrip
Amgen's second quarter sales and earnings significantly beat market consensus expectations, but the financial report was overshadowed by news that the company will cut 2,400 to 2,900 jobs and reinvest the money saved into products that may be approved in 2015.
You may also be interested in...
Levy, SVP of global development, notes that two years after launching an in-house Center for Design and Analysis, Amgen considers adaptive designs for most new studies and more than half include adaptive elements.
Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.